search
Back to results

AdVance® vs ARGUS® Sling Procedure in Male With Post Prostatectomy Stress Urinary Incontinence

Primary Purpose

Stress Urinary Incontinence

Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
AdVance® sling procedure
ARGUS Sling procedure
Sponsored by
Jewish General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stress Urinary Incontinence focused on measuring stress urinary incontinence, post prostatectomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • The subject is male
  • The subject is at least 18 years of age
  • The subject has an estimated life expectancy of more than 5 years
  • The subject has confirmed stress urinary incontinence (SUI) through medical history, urodynamics, and/or physical exam for at least 6 months
  • The subject has intrinsic sphincter deficiency due to one of the following:

post-TURP, simple open prostatectomy, radical prostatectomy completed at least 6 months prior to implantation date

  • Positive Cough Stress Test (CST):
  • Positive 24-hours Pad Test (PT):

A positive PT is confirmed with leakage of >8.O g/24h and < 400 g

  • The subject has completed urodynamics, uroflow, post-void residual, and cystoscopy as per the protocol within 6 months prior to implant
  • The subject is able and willing to complete all follow-up visits and procedures indicated in this protocol
  • The subject has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the local ethics commit-tee of the respective site

Exclusion Criteria:

  • Subjects who meet any of the following criteria are excluded from entry into the study
  • The subject is unable or unwilling to sign the Informed Consent Form (ICF) and/or comply with all follow-up requirements according to the study protocol
  • The subject has an active urogenital infection or active skin infection in region of surgery
  • The subject has serious bleeding disorders
  • The subject has incontinence due to neurogenic causes defined as multiple sclerosis, spinal cord/brain injury, CVA, detrusor-external sphincter dyssynergia, Parkinson's disease, or similar conditions
  • The subject had a previous implant to treat stress urinary incontinence
  • The subject has undergone radiation, cryosurgery, or brachy therapy to treat prostate or other pelvic cancer within 6 months
  • The subject is likely to undergo radiation therapy within the next 6 months
  • The subject has active urethral or bladder neck stricture disease, requiring continued treatment
  • The subject has urge predominant incontinence
  • The subject has an atonic bladder or a postvoid residual (PVR) ≥150mL
  • The subject has a condition or disorder likely to require future transurethral procedure
  • The subject is enrolled in a concurrent clinical trial of any treatment (drug or device) that could affect continence function without the sponsors'approval
  • Subjects who in the opinion of the investigator are unable and/or unlikely to to comprehend the nature, scope and possible consequences of the study and to follow the study procedures and instructions and complete all study related measurements.

Sites / Locations

  • Jewish General HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

AdVance

ARGUS

Arm Description

sling procedure

sling procedure

Outcomes

Primary Outcome Measures

Patient satisfaction using the Patient Global Impression of Improvement (PGI-I) score and assess change in 24-hour pad weight .

Secondary Outcome Measures

Assess change in subject satisfaction using questionnaires: ICIQ, UCLA-RAND Incontinence Index.

Full Information

First Posted
May 28, 2013
Last Updated
May 30, 2013
Sponsor
Jewish General Hospital
Collaborators
Center Hospitalier de Fleurimont,Sherbrooke University, Sunnybrook Health Sciences Centre
search

1. Study Identification

Unique Protocol Identification Number
NCT01866085
Brief Title
AdVance® vs ARGUS® Sling Procedure in Male With Post Prostatectomy Stress Urinary Incontinence
Official Title
Randomised Clinical Trial to Evaluate Efficacy of AdVance® vs ARGUS® Sling Procedure in Male With Post Prostatectomy Stress Urinary Incontinence
Study Type
Interventional

2. Study Status

Record Verification Date
May 2013
Overall Recruitment Status
Unknown status
Study Start Date
June 2012 (undefined)
Primary Completion Date
June 2014 (Anticipated)
Study Completion Date
June 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Jewish General Hospital
Collaborators
Center Hospitalier de Fleurimont,Sherbrooke University, Sunnybrook Health Sciences Centre

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study is designed to assess efficacy and subject satisfaction of two sling devices: Advance and Argus, in male patients with stress urinary incontinence after prostatectomy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stress Urinary Incontinence
Keywords
stress urinary incontinence, post prostatectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
128 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
AdVance
Arm Type
Active Comparator
Arm Description
sling procedure
Arm Title
ARGUS
Arm Type
Active Comparator
Arm Description
sling procedure
Intervention Type
Procedure
Intervention Name(s)
AdVance® sling procedure
Intervention Type
Procedure
Intervention Name(s)
ARGUS Sling procedure
Primary Outcome Measure Information:
Title
Patient satisfaction using the Patient Global Impression of Improvement (PGI-I) score and assess change in 24-hour pad weight .
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Assess change in subject satisfaction using questionnaires: ICIQ, UCLA-RAND Incontinence Index.
Time Frame
12 months
Other Pre-specified Outcome Measures:
Title
Summarize all cumulative device and procedure related adverse events
Time Frame
12 months

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The subject is male The subject is at least 18 years of age The subject has an estimated life expectancy of more than 5 years The subject has confirmed stress urinary incontinence (SUI) through medical history, urodynamics, and/or physical exam for at least 6 months The subject has intrinsic sphincter deficiency due to one of the following: post-TURP, simple open prostatectomy, radical prostatectomy completed at least 6 months prior to implantation date Positive Cough Stress Test (CST): Positive 24-hours Pad Test (PT): A positive PT is confirmed with leakage of >8.O g/24h and < 400 g The subject has completed urodynamics, uroflow, post-void residual, and cystoscopy as per the protocol within 6 months prior to implant The subject is able and willing to complete all follow-up visits and procedures indicated in this protocol The subject has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the local ethics commit-tee of the respective site Exclusion Criteria: Subjects who meet any of the following criteria are excluded from entry into the study The subject is unable or unwilling to sign the Informed Consent Form (ICF) and/or comply with all follow-up requirements according to the study protocol The subject has an active urogenital infection or active skin infection in region of surgery The subject has serious bleeding disorders The subject has incontinence due to neurogenic causes defined as multiple sclerosis, spinal cord/brain injury, CVA, detrusor-external sphincter dyssynergia, Parkinson's disease, or similar conditions The subject had a previous implant to treat stress urinary incontinence The subject has undergone radiation, cryosurgery, or brachy therapy to treat prostate or other pelvic cancer within 6 months The subject is likely to undergo radiation therapy within the next 6 months The subject has active urethral or bladder neck stricture disease, requiring continued treatment The subject has urge predominant incontinence The subject has an atonic bladder or a postvoid residual (PVR) ≥150mL The subject has a condition or disorder likely to require future transurethral procedure The subject is enrolled in a concurrent clinical trial of any treatment (drug or device) that could affect continence function without the sponsors'approval Subjects who in the opinion of the investigator are unable and/or unlikely to to comprehend the nature, scope and possible consequences of the study and to follow the study procedures and instructions and complete all study related measurements.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jacques Corcos, MD
Phone
1-514-340-8222
Ext
5166
Email
jcorcos@jgh.mcgill.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Oleg Loutochin
Phone
1-514-340-8222
Ext
1627
Email
oloutochin@jgh.mcgill.ca
Facility Information:
Facility Name
Jewish General Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1E2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacques Corcos, MD
Phone
1-514-340-8222
Ext
5166
Email
jcorcos@jgh.mcgill.ca
Phone
1-514-340-8222
Ext
1627
Email
oloutochin@jgh.mcgill.ca
First Name & Middle Initial & Last Name & Degree
Jacques Corcos, MD

12. IPD Sharing Statement

Learn more about this trial

AdVance® vs ARGUS® Sling Procedure in Male With Post Prostatectomy Stress Urinary Incontinence

We'll reach out to this number within 24 hrs